<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35349417</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0392-856X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>40 Suppl 134</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical and experimental rheumatology</Title>
          <ISOAbbreviation>Clin Exp Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study.</ArticleTitle>
        <Pagination>
          <StartPage>27</StartPage>
          <EndPage>31</EndPage>
          <MedlinePgn>27-31</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.55563/clinexprheumatol/bjb2gf</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES">Although antisynthetase antibodies (ARS) are the established markers of the so-called antisynthetase syndrome (ASSD), in these patients the concomitant positivity of anti-Ro52 antibodies, reported in up to the 50% of cases, is not rare. Several studies focused on the effect of different ARS specificities on the evolution of ASSD, the most recent showing no effects. On the contrary, the role of co-occurring anti-Ro52 antibodies in ASSD is still debated. We investigated the potential of anti-Ro52 antibodies in identifying a clinical phenotype of ASSD or influencing prognosis, irrespectively to the underlying ARS specificity.</AbstractText>
          <AbstractText Label="METHODS">Retrospective analysis of clinical, imaging and laboratory characteristics, therapeutic approaches and outcome at baseline and at last follow-up, of 60 ASSD patients progressively enrolled at our Hospital.</AbstractText>
          <AbstractText Label="RESULTS">We identified 34 anti-Ro+ and 26 anti-Ro- ASSD patients. Classic triad prevalence at baseline was similar between the two groups, whereas interstitial lung disease (ILD) (p value=0.01) and myositis (p value=0.03) were significantly more prevalent in anti-Ro52+ and in anti-Ro52- patients at last follow up, respectively. No differences in therapeutic approaches, oxygen need and ILD patterns were observed. Overall mortality was 25% (15 subjects). No differences in mortality, overall and disease related, between anti-Ro52+ and anti-Ro52- patients were observed (p value=0.764), despite the more frequent ILD occurrence in anti-Ro52+ patients. Survival curves were not different at any time point (Log-rank test, p value 0.98).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Anti-Ro52 antibodies affect time course and clinical characteristics of ASSD. Although ILD is significantly more associated to anti-Ro52 antibodies, no difference in mortality was observed compared to anti-Ro52 negative patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Bozzalla-Cassione</LastName>
            <ForeName>Emanuele</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET. emanuele.bozzalla@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zanframundo</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Biglia</LastName>
            <ForeName>Alessandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bellis</LastName>
            <ForeName>Elisa</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bozzini</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Codullo</LastName>
            <ForeName>Veronica</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vertui</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Lung Transplant Centre Unit, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alpini</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biochemical-Clinical Analyses, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Valentini</LastName>
            <ForeName>Adele</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Radiology Unit, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Preda</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Radiology Unit, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montecucco</LastName>
            <ForeName>Carlomaurizio</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meloni</LastName>
            <ForeName>Federica</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Lung Transplant Centre Unit, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cavagna</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Clin Exp Rheumatol</MedlineTA>
        <NlmUniqueID>8308521</NlmUniqueID>
        <ISSNLinking>0392-856X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C537778">Antisynthetase syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>17</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35349417</ArticleId>
        <ArticleId IdType="doi">10.55563/clinexprheumatol/bjb2gf</ArticleId>
        <ArticleId IdType="pii">18090</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
